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INTRODUCTION 
Congenital hypothyroidism (CH) is the commonest preventable cause of mental 
retardation in children. Diagnosis and initiation of Thyroxine supplements as early as 
possible after birth, preferably within the first two weeks of life is imperative to 
prevent neurocognitive impairment. However the clinical symptoms and signs of 
congenital hypothyroidism take several weeks to manifest causing major delay in 
diagnosing this condition.  The introduction of newborn thyroid screening and early 
initiation of Thyroxine supplements in children with congenital hypothyroidism have 
dramatically improved their neurocognitive outcome. Over the last two to three  
decades universal newborn screening(NBS) for CH is available in all the developed 
and some of the developing countries. 
In Christian Medical College, Vellore, screening for congenital hypothyroidism has 
been implemented since July 2001. All babies born at our hospital above 26 weeks of 
gestational age have cord blood sent for TSH assay as part of standard of care. Those 
with cord blood TSH above the cut-off level are recalled for confirmatory sampling. A 
diagnosis of primary congenital hypothyroidism is made if TSH is elevated and Free 
T4 level is low for the age. In the initial 8 months of our screening programme, the 
cord blood TSH cut-off was 20 mIU/L. Using this cut-off level, none of the 
5209babies screened were confirmed to have congenital hypothyroidism, therefore the 
screen cut-off was increased to 25mIU/L in April 2002   and  has remained the same 
since then. Over the last 16 years we have confirmed primary congenital 
hypothyroidism in 123 babies. .  
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Unfortunately there is no national NBS programme for congenital  hypothyroidism  in 
India. Several private and government facilities have initiated their own newborn 
screening programmes. There is no consensus as to what is the most appropriate TSH 
cut off value with different centers using values ranging from 10mIU/L to 40mIU/L. 
Keeping in mind the devastating and irreversible adverse  neurodevelopmental 
outcome of  a delayed or missed diagnosis of CH in children, the need of the hour for  
India is   to initiate universal NBS for CH with clearly laid out guidelines including 
screening cut-offs to facilitate early diagnosis and prompt initiation of therapy.. 
One of the road blocks to implementation of national newborn screening for 
congenital hypothyroidism may be its doubtful cost benefit ratio. In the light of our 
vast experience with a successful ongoing NBS programme, this study was proposed 
in order to identify an ideal  cord blood TSH level  which not only has high sensitivity 
as a screening tool for congenital hypothyroidism,  but  also has an acceptable recall 
rate. 
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LITERATURE REVIEW 
INTRODUCTION 
The development of the Thyroid gland is mediated and regulated by the coordinated 
expression of numerous developmental transcription factors like the thyroid 
transcription factor-1, thyroid transcription factor-2 and paired homeobox-8, which 
are expressed selectively in the thyroid gland.[1] The correct combination of the 
above factors result in thyroid cell development as well as the induction of thyroid-
specific genes - thyroglobulin, thyroid peroxidase, the sodium-iodide cotransporter 
and the thyroid-stimulating hormone receptor.[2] 
 
Mutations in the genes coding these transcription factors are responsible for rare 
causes of thyroid agenesis or dyshormonogenesis. However, the causes of most of the 
cases of congenital hypothyroidism remain idiopathic. The reported prevalence of CH 
in the developed countries has changed from  1:7000-10,000 prior to the NBS era, to 
1:3000- 4000 (1970s, USA) to   1:2273( 2007, US)[3]. 
However the prevalence is much higher in several other countries including 1:748 
(Iran), 1:1600Pakistan)[4,5]. In India prevalence of CH is different in different 
states1:1700 (Hyderabad), 1:3400 (Chandigarh) and 1: 1700 (Lucknow)[6].  
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Hence universal newbornscreening is now the standard in most countries, as early 
thyroid hormone replacement in newborns with congenital hypothyroidism can 
prevent or minimise  potentially severe developmental abnormalities associated with 
the illness.[7] 
REGULATION OF THYROID FUNCTION 
The thyroid axis is an endocrine feedback loop, where the levels of thyroid hormones 
in the body are closely regulated to maintain metabolic homeostasis. Thyroid releasing 
hormone (TRH) produced in the hypothalamus stimulates  the production of the 
Thyroid Stimulating Hormone (TSH) which in turn will stimulate thyroid hormone 
synthesis and secretion from the thyroid gland. On the other hand, thyroid hormones 
provides a negative feedback predominantly through the thyroid- hormone receptor β2 
(TRβ2) which inhibits TRH and TSH production (Figure 1).  
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Figure 1Regulation of thyroid gland (Adapted from Harrisons textbook of medicine, 
19
th
 edition) 
The “set-point” in the above thyroid axis is established by TSH, which is secreted by 
the thyrotropes in the anterior pituitary gland and like other pituitary hormones is 
secreted in a pulsatile manner.  It is composed of 2 subunits – α and β subunits – with 
the β subunits being unique to TSH; whereas the α subunit is common to other 
glycoprotein hormones like the follicular stimulating hormone (FSH), luteinizing 
hormone (LH) and Human chorionic Gonadotropin (hCG).  
THYROID HORMONE SYNTHESIS 
The follicular cells of the thyroid gland produce thyroglobulin, a large glycoprotein 
from which the thyroid hormones are synthesized. Thyroglobulin is then iodinated on 
tyrosine subunits which are then bound by ether linkages. The release of T3 or T4 into 
the blood stream results after thyroglobulin reuptake occurs by the follicular cells of 
the thyroid gland, within which proteolysis occurs as the final step.   
Iodide uptake is the first and most critical step in the synthesis of thyroid hormones. 
Most of the iodine which is ingested is bound to albumin in the serum and constitutes 
the fraction which is absorbed by the body for thyroid hormone production. Unbound 
iodine is almost entirely excreted in the urine.   
The thyroid gland can extract iodine from the circulation in a very efficient manner. 
Tracer studies show that up to 10–25% of radioactive iodine can be taken up by a 
normal thyroid gland over a 24 hour period, and this value can increase up to 90% in 
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disease states like Graves‟ disease.  This process of Iodide uptake is mediated by 
Sodium iodide symporter (NIS), which is present at the basolateral membrane of the 
thyroid follicular cells.  This symporter is most densely expressed in the thyroid gland, 
but low levels can be found in the membranes of the placenta, the lactating breasts and 
the salivary glands.  
This iodide transport mechanism is also highly regulated that it allows a wide range of 
adaptation depending on the variations in dietary availability of iodine. Low iodine in 
the diet causes in an increase in the levels of Sodium iodide symporter (NIS) and 
results in increase iodide uptake.High iodine levels leads to  suppression of NIS 
expression and subsequent iodide uptake. It is this selective expression of NIS in the 
thyroid gland that allows the use for radioisotope of iodine in isotopic scanning, 
treatment of hyperthyroidism, and radioisotope ablation of thyroid cancer and at the 
same time minimizing significant effects of the same  on other organs of the body. 
Mutation of the Sodium iodide symporter (NIS) gene is a rare cause of congenital 
hypothyroidism.  
Pendrin is another iodine transporter which is located on the apical surface of thyroid 
cells.  It mediates the efflux of iodine into the lumen of the thyroid follicles. Mutation 
of the pendrin gene results in the Pendred syndrome – a congenital disorder which is 
characterized by defective organification of iodine, goiter, and sensorineural hearing 
loss. [8] 
After iodide is absorbed into the thyroid gland, it is retained inside the cell and 
transported to the apical cell membrane of follicular cells of the thyroid gland.  
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Thyroxine peroxidase and hydrogen peroxide which is produced by dual 
oxidase(DUOX) and DUOX maturation factor (DUOXA) results in an 
organificationreaction in the follicular cells which oxidizes the iodide molecule to a 
reactive iodine atom. This combines to certain selected tyrosyl residues within the 
thyroglobulin which a large protein that is composed of 2769 amino acids.  These 
newly produced iodo -tyrosines molecules in Thyroglobulin are then coupled to each 
other via an ether bond in a reaction that is again catalysed by TPO enzyme. 
This reaction can lead to production of Either T4 or T3 depending on the number of 
iodine atoms present in the iodotyrosines molecules. Thyroglobulin can then be  taken 
back into the thyroid cell,  where it is processed in lysosomes present inthe cytoplasm 
to release T4 and T3.  The resulting uncoupled mono- and iodotyrosines are then de-
iodinated by the enzyme dehalogenase which recycles the iodide that has not been 
used for synthesis of thyroid hormones.  
Defects in thyroid hormone synthesis can result in rare causes of congenital 
hypothyroidism. The majority of these disorders are a result of recessive mutations in 
TPO or Thyroglobulin. However, mutations have also been increasingly identified in 
the TSH receptor genes, pendrin, NIS, dehalogenase and hydrogen peroxide 
generation. The result of this biosynthetic defect results in the gland being incapable 
of synthesizing adequate amounts of thyroid hormones. This mostly manifest as 
congenital hypothyroidism with increased levels of TSH and a large goiter.  
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SITE OF ACTION OF THYROID STIMULATING HORMONE 
TSH, a hormone produced in the anterior pituitary gland, is responsible for regulation 
of the thyroid gland function through its action on the TSH receptors (TSHR). The 
TSH receptor is a transmembrane G protein–coupled receptor (GPCR) which is 
coupled to the alpha subunit of stimulatory G protein (GSα), which in turn activates 
adenylyl cyclase and results in the increased production of cyclic adenosine 
monophosphate (AMP).  TSH also activates phospholipase C which increases 
phosphatidylinositol turnover. 
The functional role of the TSH-R is mainly seen by the effects of naturally occurring 
mutations of the TSH-R. Recessive mutations can cause loss-of-function of the 
receptor and cause complete thyroid hypoplasia and congenital hypothyroidism. On 
the other hand, dominant mutations can result in gain of-function mutations which are 
responsible for sporadic or familial hyperthyroidism - characterized by goiter, 
hyperplasia of follicular cells and autonomous T hyper-functioning thyroid gland. 
 A majority of these activating mutations takes place in the transmembrane portion of 
the TSH receptor. Such mutations can mirror the conformational changes that takes 
place as a result of TSH binding or the action of thyroid-stimulating immunoglobulins 
(TSI) that are seen in Graves‟ disease.  These TSH-R mutations can also occur as 
somatic events which can result in clonal selection and multiplication of the affected 
thyroid follicular cell resulting in autonomously functioning thyroid nodules.  
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Although TSH is the most important hormonal regulator responsible for growth of the 
thyroid gland and its optimal functioning, other factors, which includes a variety of 
growth factors that are locally produced, can also influence Thyroid hormone 
synthesis, release and function. These factors includes insulin-like growth factor I 
(IGF-I), transforming growth factor β (TGF-β), epidermal growth factor, endothelins, 
and many other cytokines. However the quantitative roles of each of these factors are 
not yet fully understood. These factors are more important in the context of certain 
selected disease states like acromegaly, where there exist increased levels of the 
growth hormone and IGF-I levels. This is associated with enlargement of the thyroid 
gland and an increased predisposition to multi-nodular goiter (MNG). 
THYROID HORMONE ACTION 
Thyroid hormones which are in circulation in the blood stream enters the cells partly 
by passive diffusion and  also via specific cell transporters like the monocarboxylate 8 
transporter, the monocarboxylate 10 transporter and organic anion-transporting 
polypeptide 1C1. Mutations in the genes encoding these transporters have been 
identified in patients who present with X-linked psychomotor retardation and also in 
patients with thyroid function abnormalities.  
After entering the cells, the thyroid hormones act mainly via nuclear receptors, 
although, they may also have non-genomic actions by stimulating mitochondrial 
enzymatic responses which may directly have actions on blood vessels as well as the 
heart, mediated by the integrin receptors.  
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Thyroid hormones bind to nuclear thyroid hormone receptors (TRs) α and β with very 
high affinity. Both these thyroid hormone nuclear receptors are expressed in almost all 
the tissues of the body, with their relative expression levels varying among different 
organs. Thyroid hormone receptor α is particularly found in large concentrations in the 
brain, the kidneys, the gonads, in muscle and heart as well. Thyroid hormone receptor 
β however is expressed relatively higher in the pituitary gland and in the liver. In the 
pituitary gland, the thyroid hormone receptor β plays a role in feedback control of the 
thyroid axis. 
These nuclear receptors bind to specific sequences in the DNA called thyroid response 
elements (TREs), which can be found in specific regions of target genes. These 
receptors sometimes bind as homo- dimers or as heterodimers with retinoic acid X 
receptors. These activated receptors can then either stimulate gene transcription of 
myosin heavy chain α, or can also inhibit transcription of the TSH β-subunit gene, as 
per the nature of the regulatory elements in the gene of target. 
ROLE OF THYROID HORMONE IN METABOLISM AND 
MYELINATION 
Clinical and experimental studies so far had shown that thyroid hormone is vital to the 
development of the brain. Majority of these studies were done during the postnatal 
period. Recent studies have however shown that thyroid hormone is essential to brain 
development throughout the fetal period and that the timing and severity of the thyroid 
hormone deficiency can predict the type and extent of the neurological sequelae. 
Thyroid hormone insufficiency during the  first half of pregnancy  leads to defects in 
27 
 
visual processing, attention and gross motor skills. While thyroid hormone deficiency 
that occurs later in the pregnancy leads to subnormal visuospatial skills and fine motor 
developmental delay,  deficiency that occurs in the postnatal period leads to defects in 
memory and language skills.[9] 
 
Figure 2. Figure showing the various defects in humans and rodents caused by thyroid 
hormone deficiency depending during various time period of fetal and post natal life. 
(Adapted from Zoeller RT, Rovet J. Timing of thyroid hormone action in the 
developing brain: clinical observations and experimental findings. J Neuroendocrinol 
2004;16:809–18) 
ROLE OF IODINE IN THYROID FUNCTION 
Iodine is a trace element present in low concentrations in the soil, air and sea.Iodine 
content of plant and animal foods reflects iodine content of local soil. Depletion of 
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iodine from the soil occurs due to soil erosion resulting from high rainfall or 
glaciation. 
The dietary sources of iodine are marine foods such as fish, shellfish, seaweed , milk 
and dairy products, meat and eggs. With iodinisation of salt, iodised salt is one of the 
most important daily source of iodine.  
In the human body, iodine  is found in minute amounts and is an essential substrate for 
the synthesis of thyroid hormones[10]. Thyroid gland needs 52µg of iodine every day. 
Sodium/iodide transporter transfers iodine from serum to thyroid at concentration 
gradient of 20-50 times that of plasma. 
The clinical manifestations of iodine deficiency reflect either the direct consequences 
of iodine deficiency on the thyroid or the secondary consequences of hypothyroidism 
on the thyroid hormone sensitive target tissues. If the requirements of iodine are not 
met, functional and developmental abnormalities including those of thyroid function 
occur. When the iodine deficiency is severe, endemic goitre and cretinism, endemic 
mental retardation, decreased fertility rates and increased perinatal death and infant 
mortality have been documented[11].  
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Cretinism, the most severe form of permanent mental retardation, results from 
maternal iodine deficiency in early pregnancy.  
Urinary iodine concentration is a reliable marker of iodine status in the body and is a 
gold standard for population studies. Urinary iodine concentration of 100-199 µg/L 
indicates adequate iodine status[12] 
The variations in thyroid profile noted in individuals living in iodine deficient regions 
are decreased T4 or FT4, normal or increased T3, and a normal or increased TSH 
compared to the normal population. The neonatal TSH level is reported to be a more 
reliable indicator of iodine deficiency in the population  with higher TSH levels 
during the first few weeks of life in the iodine deficient community. Delange et al 
stated that the most important and frequent alterations in thyroid function due to 
iodine deficiency occur in neonates and young infants in Europe[13]. This is 
substantiated by two important observations: 
Figure 3: The spectrum of iodine deficiency disorders as adapted from Pediatric 
Endocrine Disorders. Desai, P M, Menon VB& PSN. Orient Blackswan; 2001. 
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The risk of transient hypothyroidism in neonates is directly proportionate to the degree 
of prematurity[14]. The role played by iodine deficiency in this transient syndrome is 
supported by the disappearance of the same after supplementation with potassium 
iodide. 
An inverse relationship was established between urinary iodine concentration in new 
born population in Europe, an index of state of iodine nutrition and frequency of 
serum TSH above 50 mU/ml at day 5[15]. In contrast, of the 71 Turkish newborns 
with urinary iodine concentration <100 mcg/L, only 48% of the term neonates with 
iodine deficiency had high serum TSH levels ≥11.2mIU/L[11]. These authors 
postulated that serum thyroglobulin levels may be a better indicator of Iodine 
deficiency.The thyroglobulin level indicates iodine status over a prolonged period. 
The hypothyroid state due to iodine deficiency may be transient or permanent.A study 
conducted in Xinjiang, China revealed that the prevalence of both overt and 
subclinical hypothyroidism was higher in iodine deficient group[16,17].  
IODIZATION OF SALT – IN THE INDIAN CONTEXT 
Iodination of salt as prophylaxis for Iodine deficiency disorder began in the 1920s in 
the USA and Switzerland  pioneered by  Dr. David Marine in Akron, Ohio, USA This 
landmark study revealed that the administration of iodide tablets produced a decrease 
in the incidence of goiter in adolescents. This action was initiated in 1950s and 60s in 
Asia but gained momentum only by the late 1970s[18] 
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A landmark study was conducted in India in 1954 to establish the efficacy of 
iodination of common salt by the Government of India, the State Government of 
Punjab and the Indian Council of Medical Research in Kangra,  Himachal Pradesh. 
The region was divided into three zones- A, B and C. After evaluating baseline 
characteristics, salt fortified with potassium iodide was given to those in Zone A and 
salt fortified with Potassium Iodate to Zone C. Zone B was provided salt without 
iodine. Analysis conducted in 1962, it became clear thshowed that the prevalence of 
goiter had reduced in zone A and C and hence iodine fortified salt wasplanned for all 
the zones.n. Second surveys done in 1968 and 1972 showedthat while zones A and C 
showed continuous decline in goitre prevalence , the prevalence of goiter in Zone B 
declined only after the provision of iodised salt in 1962. [19]. 
 
Based on the success of the Kangra Valley study, the Government of India launched 
the National Goitre Control Programme (NGCP) in 1962 which was 100% centrally 
assisted. The programme aimed to identify goitre endemic regions of the country and 
supplement the intake of iodide in these regions. It focused predominantly on the 
“goitre belt” which comprised the Himalayan and Tarai regions. It was later observed 
that  IDD were reported from almost all areas of the country. Universal Salt Iodization 
(USI) as the preferred strategy to eliminate IDD was introduced in India in  1986. .  
Currently  91% of the Indian households have  access to iodized salt and 71% 
consume  adequate amounts[20].  
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CONGENITAL HYPOTHYROIDISM 
Congenital hypothyroidism is one of the most common preventable causes of mental 
retardation in the pediatric population. The prevalence of congenital hypothyroidism 
as observed in western studies is about 1:4000[21]. However a large multi-centric 
study done by AIIMS across India screening over one lakh newborns between the year 
2007 to 2012 found the prevalence to be much higher at 1:1221[22]. Our own data at 
Christian Medical College, Vellore has found the prevalence to be about 
1:1200(unpublished data). 
Screening for congenital hypothyroidism began in the early 1970s. The rationale for 
incorporation of screening for congenital hypothyroidism into the NHS(UK) was that 
they found improved CNS outcomes in those babies with CH in whom treatment was 
initiated by three months of life[23]. Through their newborn screening program, the 
NHS was largely able to eradicate the adverse neurodevelopmental outcomes that 
arise from congenital hypothyroidism[24]. It is only appropriate that India with its 
high prevalence of congenital hypothyroidism adopt a similar screening strategy so 
that this preventable cause of mental retardation can be diagnosed early and started on 
appropriate treatment, thereby reducing the morbidity and adverse outcome 
significantly. 
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GENETICS OF CONGENITAL HYPOTHYROIDISM 
The inheritance of congenital hypothyroidism is generally sporadic. However in 2% of 
the cases of thyroid dysgenesis, the inheritance maybe familial and congenital 
hypothyroidism that is caused by organification defects maybe inherited recessively. 
The genes responsible for this genetically heterogenous disorder form two major 
groups: (i) those causing thyroid gland dysgenesis and (ii) those causing 
dyshormonogenesis. The genes associated with dysgenesis of thyroid include Gsα, 
TTF-1, TTF-2, Pax-8(thyroid transcription factors) and different syndromic 
complexes involving congenital hypothyroidism. Amongst the group causing 
dyshormonogeneis, the thyroglobulin and thyroid peroxidase genes were described 
initially. However in the recent past NIS(sodium iodide transporter), PDS(Pendred 
syndrome) and THOX2(Thyroid oxidase) gene defects are also described[25,26]. 
More recently, certain mutations in DUOX2 or THOX2(enzyme dual oxidase 2) have 
been detected. These lead to dyshormonogenesis due to deficient hydrogen peroxide 
generation and its inheritance has been found to be autosomal dominant[27]. 
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Table 1: The genes responsible for congenital hypothyroidism 
 
 
 
Gene Thyroid Other systems(few features) 
TSH-R Variable TSH 
resistance 
 
TTF-1 Hypothyroidism Neonatal respiratory distress, 
hypotonia, choreoathetosis etc 
TTF-2 Agenesis Cleft palate,spiky hair 
PAX-8 Hypoplasia Activates WT1 gene 
GNAS1 TSH resistance Albright hereditary  osteodystrophy 
MCT8  T4,  T3 &TSH Central hypotonia, 
nystagmus,feeding problem 
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CLINICAL FEATURES 
The clinical features of a newborn with congenital hypothyroidism is often subtle and 
hence many infants are undiagnosed at birth[28]. This could be attributed to the 
passage of the maternal thyroxine through the placenta. The measured level of 
thyroxine in umbilical blood is found to be about 25-30% of normal[29]. Thus this 
thyroxine transferred from the mother has some protective effect on the fetal brain 
development[30]. The absence of such overt clinical signs and symptoms at birth, 
coupled with a newborn screening program that is restricted to large tertiary hospitals, 
it is important for clinicians to pick up these subtle clinical signs and symptoms which 
would help in early diagnosis and prevention of permanent neuro-developmental 
sequelae. 
SYMPTOMS OF CONGENITAL HYPOTHYROIDISM 
The initial symptoms of congenital hypothyroidism could be nondescript. However, 
the pregnancy and maternal history could provide some important clues. In about 20% 
of cases, the pregnancy may exceed beyond 42 weeks[28]. There could also be a 
history of maternal history of an autoimmune thyroid disease, a diet deficient in iodine 
or inadvertent treatment with radioactive iodine during pregnancy, which is rare. Once 
the baby is brought home, these are often found to be quiet and sleeping most of the 
day. There could also be symptoms such as hoarse cry, constipation and neonatal 
hyperbilirubinemia that lasts for more than three weeks[31]. The following table 
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illustrates some of the symptoms present in babies with congenital hypothyroidism 
during the time of newborn screening: 
 
Figure 4: Prevalence of symptoms of congenital hypothyroidism at time of diagnosis 
(modified from: Alm et al. Brit Med J 289:1171-175, 1984 [13].) 
SIGNS OF CONGENITAL HYPOTHYROIDISM 
The common signs seen on initial examination of a baby with congenital 
hypothyroidism are macroglossia, umbilical hernia and dry mottled skin. Since the 
thyroid hormone is essential for the formation and maturation of bones[32], these 
babies could have wide open posterior fontanelles, usually greater than five 
millimeter. This along with poor feeding and persistent jaundice form  the most 
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striking clinical feature[33]. In a minority of babies with dyshormonogeneis, where 
the defect is with thyroid hormone production, there may be a palpable goiter. 
 
 
Figure 5: Infant with congenital hypothyroidism. A - 3 month old infant with 
untreated CH; Picture demonstrating hypotonic posture, 
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 Infant with congenital hypothyroidism, myxedematous facies, macroglossia, and 
umbilical hernia. (adapted from LaFRANCHI S. Congenital Hypothyroidism: 
Etiologies, Diagnosis, and Management. Thyroid 1999;9:735–40. 
doi:10.1089/thy.1999.9.735.) 
 
Figure 6: Radiograph of left lower extremity of two infants, (Left)Showing absence of 
distal femoral epiphysis, (Right) Distal femur showing presence of epiphysis in a 
normal child 
These babies have a flat nasal bridge and the eyes could be mistaken for 
hypertelorism. The mouth may remain open, revealing the macroglossia. Further 
evaluation reveals a protuberant abdomen with an umbilical hernia. Skin appears cold 
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and mottled suggesting circulatory compromise. Neurological features include 
hypotonia and delayed reflexes. Absent femoral epiphysis on the x-ray can be seen in 
about 54% of the cases[34]. 
THYROID DYSGENESIS 
Thyroid dysgenesis is the most common developmental defect causing congenital 
hypothyroidism and currently accounts for half the cases. This condition is 
characterized by a defect in migration of the median anlage, usually resulting in an 
ectopic lingual thyroid. The affected individuals are generally left with these lingual 
thyroids as the only thyroid tissue in the body. However, histologically these ectopic 
thyroid tissue reveals a normal follicular architecture[35]. Therefore, the 
hypothyroidism that is associated with this condition varies in its severity and depends 
on the number of cells. In about 33% cases of thyroid dysgenesis, even the most 
sensitive thyroid scan is unable to pick up remnants of thyroid tissue(aplasia). In the 
remaining 66% of the cases, thyroid tissue is picked up anywhere between the 
tongue(lingual) to its normal position in the neck(hypoplasia)[36]. 
Thyroid dysgenesis is generally sporadic in its inheritance. However familial cases 
occur more frequently than by chance alone.  Another important aspect is the 
discordancy that is almost always noticed amongst monozygotic twins. In order to 
reconcile with discrepant findings, a two hit hypothesis, combining genetic 
susceptibility and early post-zygotic mutations have been proposed[37]. 
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THYROID HORMONE DYSHORMONOGENESIS 
Thyroid hormone dyshormonogenesis occurs when there is a defect in one or more of 
the steps leading to thyroid hormone formation and is its seen in about 15-20% cases 
of congenital hypothyroidism[38]. In these babies a the decreased thyroid hormone 
formation leads to an increased production of TSH hormone by the anterior pituitary 
through its negative feedback mechanism. This leads to an increase in the size of the 
thyroid gland and consequently many of these babies may either be born with a goiter 
or may develop it later, especially when diagnosis is delayed and treatment with 
levothyroxine is not initiated early[39]. 
Iodine and tyrosine form the major substrates in thyroid hormone synthesis. Iodine, a 
trace element could be one of the rate limiting factors in the synthesis of thyroxine. 
The process of thyroxine biosynthesis is initiated by the binding of TSH to the TSH 
receptor on the follicular cell and cAMP activation. Various processes are stimulated 
by cAMP and this includes cell membrane transport of iodine, synthesis of 
thyroglobulin, oxidation and organification of the trapped iodine, intracellular 
phagolysosome formation and hydrolysis of thyroglobulin in order to release 
iodotyrosines (monoiodotyrosine[MIT] & diiodotyrosine[DIT]) and iodothyronine(T4 
&T3) residues, de-iodinisation of MIT & DIT by dehaologenase, leading to recycling 
of  intracellular iodine and release of the T4 and T3 into circulation[37].  
The cause thyroid dyshormonogenesisincude decrease in iodine trapping, defects in 
organification of trapped iodine, abnormalities in the thyroglobulin structure and 
defects in iodotyrosine de-iodination and recycling. From various molecular studies, 
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mutations in thyroperoxidase appears to be the most common etiology for thyroid 
dyshormogenesis. Identification of the specific disorder is however not of great 
importance as it has no bearing on the management[40]. 
SODIUM-IODINE SYMPORTER DEFECTS 
Iodine transport across the cell membrane of the thyroid follicular cell from plasma to 
cytosol forms the first step in the synthesis of thyroid hormone. In normal individuals 
the iodine pump in the thyroid cell membrane is able to generate a thyroid/serum 
concentration gradient above 20 to 30. When the thyroid gland is stimulated by certain 
conditions such as low iodine diet, thyroid stimulation immunoglobulins, TSH, or 
drugs impairing the efficiency of thyroid hormone synthesis, this gradient can increase 
several hundredfold. The mapping of the  sodium-iodine symporter gene(SCL5A5) 
located on chromosome 19 has allowed the detection of disease causing mutations in 
31 babies with iodine transport defect as of 2006[37,41]. 
PENDRED SYNDROME 
Pendred syndrome is a disorder that is transmitted my autosomal recessive inheritance 
and is characterized by goiter and congenital bilateral sensory neural hearing loss. 
Recent studies show that it is the cause of about 10% of the cases of congenital 
deafness[42]. The etiology of deafness in pendred syndrome remains controversial but 
CT scan of the temporal bone characteristically shows dilated semicircular canals(an 
abnormality that is also known as “Mondini‟s cochlea”). The thyroid phenotype in this 
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condition is usually mild and its severity appears to depend on the nutritional iodine 
intake. Pendred syndrome is rarely picked up by newborn TSH screening[43]. 
Overtime, the affected children develop goiter and subtle hypothyroidism. 
The gene responsible for this condition is identified to be SLC26A4 and is mapped to 
chromosome 7, and the protein pendrin is found to be a multifunctional anion 
exchanger. Pendrin is expressed mainly in the inner ear, thyroid and kidney. In 
thyroid, pendrin is localized to the thyrocyte apical membrane where it is involved in 
mediating influx of iodine[44]. 
THYROPEROXIDASE DEFECT 
Organification of iodide requires two processes: oxidation of the iodide and iodination 
of the thyroglobulin bound tyrosine. The trapped iodide is first oxidized into an active 
intermediate, following which iodination of the thyroglobulin bound tyrosyl residues 
form iodothyrosines MIT and DIT. This iodination and coupling of tyrosyl is 
catalyzed by the thyroid peroxidase enzyme system in association with NADPH 
oxidases. The presentation of thyroid peroxidase deficiency is goitrous congenital 
hypothyroidism that is usually permanent with high serum levels of thyroglobulin and 
a scintiscanning showing high uptake[45]. 
The gene coding thyroid peroxidase is localized to chromosome 7 and the encoded 
glycoprotein is located on the apical membrane of the individual thyroid follicular 
cell.Though a variety of different mutations are described for this condition, attempts 
to identify a systematic genotype-phenotype correlation have been unsuccessful[46].  
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DEFECTS IN H2O2 GENERATION 
Iodination of thyroglobulin catalyzed by thyroperoxidase and subsequent oxidative 
coupling of the iodinated tyrosyl residues to a protein bound iodothyronine is one of 
the main reaction in thyroid hormone synthesis[47]. When the supple of iodine is  
sufficient, availability of hydrogen peroxidase (H2O2) is the rate limiting factor for 
both these steps. DUOX2 (NADPH oxidase complex of dual oxidase 2) and 
DUOXA2 (DUOX maturation factor 2) are the primary enzymes required for feeding 
the H2O2 to thyroid peroxidase at the apical plasma membrane. The biological effects 
of thyrotropin receptor is mostly mediated by Gs/adenyl cyclase / cAMP pathway and 
the Gq/phospholipase C beta cascade is responsible for inducing H2O2 generation via 
its synergestic effect causing increased calcium and protein kinase C activation on the 
DUOX2 and DUOXA2. Defects in the generation of the thyroidal H202 and loss of 
function mutations in DUOXA2 and DUOX2 have been identified in babies with 
congenital hypothyroidism[48]. 
WHAT IS THE NEED FOR A NEWBORN SCREENING PROGRAMME 
FOR CONGENITAL HYPOTHYROIDISM? 
As described above, thyroid hormones are absolutely essential for various metabolic 
functions as well myelination of the developing brain. Deficiency of thyroid 
hormones during critical periods of development results  in severe and irreversible 
developmental retardation. congenital hypothyroidism is the most preventable cause 
of mental retardation in children.  
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Unfortunately the clinical symptoms of congenital hypothyroidism may take several 
weeks to months  after birth to manifest. Therefore  in the pre-newborn screening era, 
< 10% of children with congenital hypothyroidism were diagnosed by 1 month of 
age[49]. This was reported by Jacobsen et al in 1981. Between  1970-1975, only 10% 
of the Danish babies with congenital hypothyroidism were diagnosed in the first 
month of life. By the 3
rd
 month, 35% of them were diagnosed and even at  one year of 
age, only 70% with CH were diagnosed. Approximately 30% children remained 
undiagnosed till 3-4
h
 years of age.[49]. In the 21
st
 century, similar findings were 
reported from a single hospital in New Delhi where between 1997-2010,260 children 
with CH presented of which 34 presentedat > 5 yrs of age[50] 
Delayed diagnosis and initiation of treatment causes irreversible neurodevelopmental 
sequelae in children, in fact several IQpoints are lost with every week delay in 
treatment(ref Fig7 below). Therefore it is imperative that CH is identified as early as 
possible after birth and treatment initiated. The only way to identify CH early is by 
instituting NBS for all babies. With minimal  cost of diagnosis, treatment and 
excellent outcome, NBS for CH is one of the most cost-effective screening 
programmes.   
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Figure7: Graph showing the relation between loss of IQ points and the delay in 
starting thyroxine in congenital hypothyroidism.(Adapted fromLa Franchi SH, Austin 
J. How should we be treating children with congenital hypothyroidism JPEM 2007 ) 
EVOLUTION OF NEWBORN SCREENING FOR CONGENITAL 
HYPOTHYROIDISM 
The concept of NBS for phenylketonuria using dried blood spot was first introduced 
by Prof.Guthrie in 1960[ref]. Screening for congenital hypothyroidism was added on 
in 1965. It was introduced  in Quebec, Canada in the 1970s. In the  mid 1970‟s it was 
observed that  incidence ofcongenital hypothyroidism was twice as that of 
phenylketonuria.[51]Over the next two decades NBS for CH  was adopted by most 
the developed nations of the world.In all these countries national newborn screening  
is entirely funded by the government. In recent years many of the developing 
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countries also have initiated  screening programmes which combine several metabolic 
and endocrine disorders.  
In India, NBS for  CH was first introduced at Wadia Hospital, Mumbai in 1982 as a 
pilot programme[52].In 2007ICMR initiated a pilot study to screen CH and CAH at 5 
regional centres to represent the North, West, South, Central and Eastern India to 
screen a target of 100,000 babies[53].Following this initiative, Goa was the first state 
to initiate state level government based comprehensive NBS “Heel to Heal” in 2008. 
This was followed by government sponsored  screening programs at selected districts 
of Chandigarh, Gujarat,  Kerala,Tamil Nadu and Delhi.In the last decade, NBS was 
started by few hospitals in several parts of India both in the private sector as well as at 
government facilities. 
Christian  Medical College, Vellore is a tertiary hospital with ~2800 inpatients and 
~7000 outpatients every day.  There are ~40-50 deliveries every day. An ongoing 
NBS for CH was introduced in July 2001 and has been ongoing since then. Having 
completed screening 1,65,637 babies, this is the largest existing cohort in India from a 
single institution.  
PRIMARY TSH VERSUS PRIMARY T4 WITH TSH BACK-UP 
SAMPLING 
In most countries such as USA, Canada, Mexico and Europe, primary TSH is done 
with back up T4 in those patients with an elevated primary TSH value. However, 
using this approach patients with thyroid binding globulin deficiency, 
hypothyroxinemia and central hypothyroidism will be missed, as in these babies the 
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elevation in the TSH is delayed. The other issue with this approach is that, with most 
centres discharging the mothers and babies before 48 hours of life, collecting the 
primary TSH sample in the first 48 hours can lead to a falsely high TSH value which 
is due to the normal physiological TSH surge and not due to any thyroid disorder. 
With the recent improvement in the TSH assay techniques using nonradioactive 
assays, we are currently able to more sensitively separate abnormal and normal TSH 
concentration. This has hence been instrumental in many countries looking to the 
primary TSH technique for their screening approach[54]. 
The second approach is a primary filter paper sample of T4 with a back up TSH done  
in those babies who had a low primary T4 concentration. This approach is useful in 
diagnosing babies with CH who have an initial low T4 with elevated TSH. This 
approach also helps in diagnosing infants with central hypothyroidism, thyroglobulin 
deficiency and hyperthyroxinemia. The disadvantage of this approach is that it will 
miss those cases of CH in which there is an initial normal T4 with delayed elevation 
of TSH[54].Another important consideration for the primary T4 approach is the more 
cost it entails.  
Primary TSH screen is more sensitive and specific for the diagnosis of primary CH. 
Overall, primary TSH-based CH screening is more practical and cost-effective and  is 
followed in most parts of the world. 
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CORD BLOOD VERSUS POSTNATAL SAMPLING- WHICH IS MORE 
FEASIBLE IN INDIA? 
It  is well known that at birth the mean CBTSH is ~10 mU/L[55]followed by a surge 
within 30 minutes which peaks by 24 hours of age  to 60-70mU/L . This gradually 
declines to normal range by 72 hours. Because of this physiological pattern, TSH 
sampling for newborn screening should be collected either from the cord blood 
(before the surge occurs) or after 72 hours after birth to minimize high false positivity 
and recall rates. 
In India, 70- 80 % mothers are discharged within 48 hours after delivery. If NBS  is 
based on sampling > 72 hours of age, several children may miss creening because of 
early post-natal discharge. Post-discharge sampling relies on parents to bring back to 
hospital a “healthy normal” newborn baby for “blood” test. Unless there are facilities 
for home visits by health workers to collect dried blood spot samples, this may result 
in high rate of “missed screening”. It is important to remember that the major 
disadvantages with CB screening are that simultaneous screening for other IEM not 
possible, only institutional deliveries are covered, may miss out rare conditions like 
central hypothyroidism, primary CH with delayed rise and congenital TBG deficiency. 
With the rate of institutional deliveries steadily increasing in India[56], using CBTSH  
TSH CUT-OFFS  USED IN SCREENING PROGRAMMES 
There is no consensus as to what is the most appropriate CBTSH to be used in 
screening programmes. Various centres across the country have been using different 
cut-off levels depending on their available data and experience. Devi et al considered 
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20µU/ml as an abnormal CBTSH in their study. However data from other studies use 
CBTSH values ranging from 9 µU/ml to 40 µU/ml as their set cut offs[57]. 
Considering that CBTSH is probably the most practical option of CH screening in 
India, it is important that a consensus cut off value for CBTSH is established so that 
centres all over the country could adopt it. 
RESCREENING HIGH RISK INFANTS 
International guidelines recommend that rescreening of all high risk newborns need to 
be done at 2 to 6 weeks of like. The high risk newborns include very low birth weight, 
premature and critically ill babies. The reason for the necessity of a delayed sample in 
premature babies is the relative prematurity of the hypothalamic-pituitary axis. Thus it 
is recommended that preterm babies have TSH samples done at 2, 6 and 10 weeks or 
when the baby is 1500 grams. The other reasons for a delayed rise in the TSH would 
be use of drugs such as steroids and dopamine. Though serial monitoring is 
recommended for these high risk infants, cost constraints and limited resources have 
made it difficult for most developing countries to establish it as a norm[58]. 
CORD BLOOD VS DAY 4 SAMPLING FOR NEWBORN SCREENING 
In 1972 when newborn screening was first introduced in Quebec, 47000 newborns 
were screened over 3 years and 7 cases of congenital hypothyroidism was picked up. 
In view of the high frequency of false positives, delay in diagnosis and the increased 
cost involved, reference cut off values had to be devised. 
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In the year 1976, Walfish et al published in the Lancet that diagnosis of congenital 
hypothyroidism by cord blood TSH was a more sensitive and specific testwhen 
compared to T4 concentrations done on day 4 of life that had a high false positive rate. 
The author however concluded that T4 testing supplemented by TSH estimation 
would be the ideal screening modality. However doing both tests is not cost effective 
and is used only in few countries. Most centers in the USA and Canada prefer using 
the primary T4 testing approach while TSH testing is done mostly in Europe[59]. 
In 1982 the neonatal thyroid screening conference was held at Tokyo and they 
recommended that newborn screening programmed should be based on TSH 
concentrations in serum. It also recommended that this could be achieved by 
measuring TSH concentration obtained from dried blood spots on day 4 of life or by 
measuring T4 supplemented by TSH on the same filter paper only in those newborns 
who have a low T4 concentration. 
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Figure 8. Approach to newborn screening and management of congenital 
hypothyroidism. Adapted from update of Newborn Screening and Therapy for 
Congenital Hypothyroidism | FROM THE AMERICAN ACADEMY OF PEDIATRICS 
[54] 
CBTSH VS DAY 4 SAMPLING – PRACTICAL CONSIDERATIONS 
The ideal method of newborn screening would be to do a filter paper sample for TSH 
and T4 on day 2 to 4 of life. It is preferable that blood samples are collected after day 
three of life as, even in normal babies there is a physiological surge in TSH levels 
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during labour which normalizes by day three of life. In most centers a primary TSH is 
done on day three of life with back up T4 being done if the TSH is abnormal. This 
method may however miss congenital hypothyroidism in three scenarios ie. TBG 
deficiency, hypothalamic-pitutary hypothyroidism and hypothyoxinemia with delayed 
elevation of TSH. Doing only a primary T4 sample would miss congenital 
hypothyroidism with delayed elevation of TSH with an initial normal T4[60]. 
In developing countries like India where follow up of patients after day three is 
difficult, one practical option would be to use cord blood TSH level as a screening 
tool. However this modality has certain drawbacks as the cord TSH level is affected 
by certain factors such as the maternal age, gestation, maternal and fetal iodine status 
with higher CBTSH levels having been reported in areas with iodine 
deficiency[61,62]. Withstanding these drawbacks, cord TSH has the exemplary 
advantage that it can be easily obtained in all newborns prior to discharge from 
hospital and a second visit is necessary only if the cord TSH is found to be abnormal.  
As per the CES data of 2009, institutional deliveries in India currently stand at 72.9% 
overall and is 85.6% in urban regions. This would mean that by introducing cord 
blood TSH as a national program we would be able to screen more than 3/4ths of the 
babies that are born in India each year. This we believe makes cord TSH the most 
pragmatic option for newborn screening for CH in India. 
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AIMS 
To propose an ideal cord blood TSH cut-off level  for mass screening for congenital 
hypothyroidism in the South Indian population.  . 
 
OBJECTIVES 
1. To derive a sensitive, cost-effective cord blood TSH cut-off level  for use in 
the mass newborn screening for congenital hypothyroidism in the South 
Indian population. 
2. To propose this cord blood TSH level as a guideline to initiate national 
newborn thyroid screening program in India 
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METHODOLOGY 
STUDY SETTING 
Christian Medical College (CMC), Vellore is one of the first institutions in the 
country to initiate mass newborn thyroid screening programme CMC is a 2800  
bedded tertiary care referral hospital located at Vellore in the southern state of Tamil 
Nadu.We have an ongoing screening programme and cord blood TSH (CBTSH) is 
being performed as standard of care for all babies born at our institution since  July 
2001.Babieswith cord blood above the cut-off level are recalled and sampled to 
confirm or rule out congenital hypothyroidism. In the initial 8 months of the screening 
programme, our CBTSH cut-off was 20 mIU/L and thereafter 25mIU/L. This study 
titled „Ideal cord blood TSH cut-off level for mass newborn thyroid screening in the 
South Indian population‟ is an analysis of the data from our screening programme. We 
also prospectively recruited babies with cord blood TSH 20-24.99mIU/L during the 
study period. The sampling for the prospective wing was conducted in the Paediatric 
endocrinology project room located at the ISSCC building of the hospital or in the 
neonatal ICU.The departments involved in this study were the Paediatric 
Endocrinology division, Departments of Neonatology and Clinical Biochemistry.  
STUDY DESIGN 
There were two components to this study. The prospective component of the study 
involved recalling all babies born between January 2017- August 2017 with CBTSH 
between 20-24.9mIU/l, after 72 hours of age for repeat sampling of TSH/T4/FT4 
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levels. This part of the study also involved analyzing the initial 8 months of our 
screening programme data when the CBTSH cut-off was 20 mIU/L.  
The second component involved analysis of data of  all babies from the screening 
programme from July  2001 till June 2017 who had  cord TSH between 25mIU/L to 
30mIU/L. The correlation between CBTSH for every value between 25-30mIU/L and 
repeat TSH/T4 and FT4 levels wereanalyzed and a positive predictive value for each 
cord blood TSH level was derived.  
The prospective data obtained wasanalysedto  evaluate whether children with CBTSH 
between 20mIU/L- 24.9mIU/L are being diagnosed with CH. The screening data  
analysis was  used to  derive an ideal CBTSH cut-off for mass newborn thyroid 
screening with high sensitivity and low false positivity. The inclusion and exclusion 
criteria were: 
INCLUSION CRITERIA : 
1. Prospective arm: All babies born > 26 weeks of gestation born in CMC 
Hospital during the study period with CBTSH levels between 20-24.9 
mIU/L. 
2. Screening data analysis involves data from all the participants of newborn 
thyroid screening programme in CMC between June 2001- July 2017 
with CBTSH levels between 25-30mIU/L. 
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EXCLUSION CRITERIA: 
1. All babies who were critically ill in the first 72 hours requiring NICU 
admission. 
2. Babies in whom  screening was  missed at birth 
3. In the prospective arm, babies whose parents did not consent to return for 
sampling after 72 hours of life. 
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DIAGNOSTIC ALGORITHM OF THE STUDY 
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DESCRIPTION OF VARIABLES AND OUTCOMES 
The variables studies in this study are cord TSH, collected at the time of delivery and 
TSH, T4 and FTC done after day three of life in those babies who had a high cord 
TSH value. When venous blood sample is used to measure TSH it is expressed as 
serum units. Assays on dried blood spot samples are expressed as whole blood units. 
Whole blood units may be converted to serum units by multiplying by 2.2. In this 
study TSH is uniformly mentioned as serum units. 
The primary outcome measured here is a diagnosis of congenital hypothyroidism 
made in those babies who were found to have high cord blood TSH concentrations 
and then went on to have an abnormal TSH, T4 and FTC level when it was repeated 
after day three of life. 
DATA SOURCE MEASUREMENT AND MANAGEMENT 
All newborns born in CMC > 26 weeks of gestation have their cord blood TSH 
screening done as routine standard of care. During the study period, those with 
CBTSH between 20-25 mIu/l wererecruited into the study after parental consent and 
recalled for repeat sampling beyond 72 hours of age. Cord blood TSH and repeat 
venous  samples of TSH, T4 and FT4 were analysed at the biochemistry lab using the 
CENTAUR automated chemi-luminiscence imunoassay. 
All qualitative and quantitative variables in the prospective component of the study 
was entered into a clinical proforma. The clinical proforma used in this study is 
attached as Annexure I. 
59 
 
The data in the retrospective component of the study was obtained from the Paediatric 
endocrine database maintained in the unit since the inception of the newborn 
screening program in the year 2001. 
BIAS 
All babies who had CBTSH levels between 20-24.9 mIU/L during the study period 
were invited to participate . Only those children who were unwell needing NICU 
admission and those whose parents refusedparticipationwere excluded thereby 
minimising the potential selection bias. 
SAMPLE SIZE CALCULATION 
In the retrospective component of the study all newborn babies born between July 
2001 to June 2017 for whom cord blood TSH was done were included in the study. 
In the prospective component of the study, sample size calculation was done on the 
basis of our own screening data. . In the period between July 2001 and December 
2015 cord blood TSH was performed on 1,44,636 babies and a diagnosis of  
congenital hypothyroidism was confirmed on 123 babies.This leads to a disease 
incidence of 0.8 per 1000, which was used as the statistical input for sample size 
calculation. The sample size was calculated using nMaster software version 2.0. 
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With proportion of 0.08 and absolute precision of 5% and for the 95% confidence 
interval, the sample size was calculated as 113.  
STATISTICAL METHODS 
For continuous data, the descriptive statistics n, mean, SD, median, IQR, minimum 
and maximum were used. For categorical data, the number of patients and percentage 
were calculated. Based on the normality of data, the parametric t test or non-
parametric Mann Whitney test was used.  Data was analysed by performing chi square 
and Fischer‟s test where applicable. 
For each interval of cord TSH, the number and percentage were presented with 
histogram to examine the distribution of the data. The cut-off points of indices of cord 
TSH for predicting a diagnosis of congenital hypothyroidism was obtained by receiver 
operated characteristic (ROC) curve analysis. For each cut-off point, sensitivity, 
specificity, positive and negative predictive values for detecting congenital 
hypothyroidism were obtained.  
Using verification bias, point estimates and confidence intervals were calculated.  
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P-values  are  reported as specified by the statistical software used, at least up to four 
decimal places. P-values less than 0.0001 are reported as provided by statistical 
software (e.g. '<0.0001'). All tests were two-sided at α=0.05 level of significance.  All 
statistical analysis were done using SPSS software version 17.0 or later. 
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RESULTS 
TSH level is uniformly mentioned as serum units. 
CBTSH SCREENING JULY 2001-AUGUST 2017 
 
Table 2: CBTSH in CMC Hospital (July 2001- August 2017) 
 
 
Total deliveries 
1,65,637 
 
Total screened 
1,64,163 
 
Missed primary  screening 
1,264(0.76%) 
Total recalled 5488 (3.31%) 
Total resampled 4224 (2.54%) 
Missed resampling 1264 (23%) 
Recall rate 2.54% 
Primary CH confirmed 123 
 
Etiology of CH 
Dyshormonogenesis 
53(44.2%) 
Dysplasia 38(31.7%) 
Ectopia 26(21.6%) 
Prevalence of CH 1: 1,346 
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MEAN CBTSH  LEVELS  (JANUARY  2005-JANUARY 2017) 
The mean CBTSH levels over a 12 year period between Jan 2005 to January 2017 was 
analysed to assess whether there was any significant change in the CBTSH over the 
years. During this period CBTSH was performed on 1,28,159 babies. The mean TSH 
during each year is illustrated in Table 2. The mean TSH concentration over the 4 year 
period between 2007-2010 was 9.645 mIU/L and had decreased to 8.830 mIU/L 
between 2015-2017. The CBTSH was least in the year 2005 when it was 
8.156±15.952 mIU/L and it reached a maximum value of 10.119±11.491 mIU/L in the 
year 2008. 
A significant difference in the mean CBTSH concentration when compared to the 
previous year was noticed in the years 2006(p=<0.001), 2009(p=0.006), 2011(p= 
0.002) and 2012(p=<0.001). Comparison of mean cord TSH concentration between 
the other years did not show any statistical difference. There was no definite pattern 
(consistent increase/ decrease) over 12 years. 
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Table 2. Mean cord TSH between 2005 -2017(n=1,28,159) 
Year                 N Mean 
CBTSH(mIU/l) 
Std. Deviation p-value* 
2005 5762 8.156 15.952 1.000 
2006 7093 10.078 14.111 <0.001* 
2007 8136 9.882 10.557 1.000 
2008 8592 10.119 11.491 1.000 
2009 9383 9.403 15.619 0.006* 
2010 10350 9.285 13.392 1.000 
2011 11535 9.982 10.362 0.002* 
2012 12549 9.045 9.377 <0.001* 
2013 13060 8.666 9.776 1.000 
2014 13455 8.725 8.923 1.000 
2015 13740 8.960 10.799 1.000 
2016 13527 8.731 14.465 1.000 
2017 959 8.356 6.679 1.000 
*Significance of difference of means with the preceding year . 
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Figure 9. Graph showing CBTSH trend between years 2005-2017. Cord TSH 
measured in mIU/L is plotted along the “x” axis and the year of birth is plotted on 
the “y” axis. 
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CBTSH LEVELS AND PRETERM BIRTHS 
The mean overallCBTSH level for each year is shown against the preterm births for 
the corresponding year in Figure 2 below.  13-17% of the deliveries in our institution 
were preterm births.  
 
Figure 10. Graph showing the comparison of mean cord TSH with the number of 
preterm deliveries each year. In this graph, year of birth is plotted along the “x”axis, 
mean CBTSH along the left “y” axis and proportion of preterm deliveries along the 
right “y” axis. 
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CBTSH BETWEEN 20 – 24.99 mIU/L 
Among the babies who had CBTSH concentration between 20-25mIU/L, two groups 
were included in the study: babies born between January 2017 to August 
2017(prospective cohort) and those born between July 2001 to March 2002 
(retrospective cohort).Overall during this period of 17 months 14,742 babies had 
CBTSH assays done. Of the 155 babies born with CBTSH 20-24.99mIU/L, 62 babies 
who returned for sampling were included in theprospective cohort. In the retrospective 
cohort, 133 of the 138 babies who  were resampled were included. Thus a total of 195 
babies were included in the analysis. 
The mean duration at which repeat thyroid function tests was done was 10 ± 12.06 
days in the prospective cohort and  6.84±8.53 days in the retrospective cohort. The 
baseline characteristics of babies with CBTSH 20 – 25mIU/L are shown in Table 3 
below 
 
 
 
 
 
 
68 
 
 
Table 3. Mean cord TSH, repeat TSH, T4 and FTC among those with CBTSH 
between 20 - 25mIU/L (Results expressed as mean(SD) 
N who had CBTSH assay over the study period: 14742 
N with CBTSH 20-24.99 mIU/L : 293 
N who had repeat sampling done: 195 
N=195 Prospective cohort (Jan 
2017 –Aug 2017) 
Retrospective cohort 
(July 2001- March 
2002) 
CBTSH(mIU/L)  22.734± 1.918 22.267±1.485 
  TSH>72 hrs(mIU/L) 3.760± 2.783 4.140±3.382 
T4(mcg/dl) 12.680±3.480 13.953±3.785 
FT4(ng/dl) 1.841± 1.387 1.878±1.135 
Confirmed CH 0 0 
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Table 3.4. Baseline characteristics of babies with cord TSH  20 - 25mIU/L in the 
retrospective cohort (n=62) 
* Complete data was not available for 7 babies 
 
 
 
Table 3.4 shows the baseline characteristics of babies in the prospective cohort. 
Majority of the babies born with a cord TSH of 20-25mIU/L were of normal 
weight(2500-4000gm). 50 of the 62 babies were born at term and 37 of them were 
born by normal vaginal delivery. 
 
 
Birth weight 
 
 
<1500gm 1501-2500gm 2501-4000gm >4000gm 
0 7 55 0 
Gestational age* <37 weeks 37 -41 weeks >41 weeks 
5 50 0 
Mode of delivery* LSCS Normal delivery Suction cup Forceps 
5 37 7 7 
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Figure 11:. Box and whisker plot showing the mean TSH concentrations at 
birth(CBTSH) and at >72 hours of age. 
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Table 5. Correlation between CBTSH and  birth weight, gestational age and 
mode of delivery 
 
The mean cord TSH concentration in the retrospective and prospective cohorts 
were22.734±1.92 mIU/L and 22.267±1.49 mIU/L respectively. There was no 
difference between the two mean CBTSH levels (p=0.065). The mean TSH 
concentration among all babies in the 20-25mIU/L group was 22.260mIU/L. The 
mean repeat TSH concentration in the prospective and retrospective cohorts were 
3.760 and 4.140mIU/L respectively.  
As shown  in table 4 there was no correlation between the cord TSH and gestational 
age, birth weight or mode of delivery in those babies who had a CBTSH between 
20.0-24.9mIU/L. There were no confirmed cases of congenital hypothyroidism in this 
group. 
Between July 2001 to March 2002, 5209 babies were born, of which 138 had CBTSH 
between 20-25mIU/L. Between the period of January 2017 to August 2017, 9533 
Characteristic Mean (S.D) p-value 
Birth weight (grams) 2979.07 (386.29) 0.254 
Gestational age (weeks) 38.68 (1.33) 0.231 
Mode of Delivery n (%)  
LSCS 5 (7.9)  
            0.468 
Normal vaginal delivery 37 (58.7) 
Forceps delivery 7 (11.1) 
Suction cup delivery 7 (11.1) 
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babies born, of which 155 babies had a  CBTSH OF 20-25mIU/L. Overall ~2%  
babies wereborn with CBTSH 20-25mIU/L  
 
 
 
 
 
 
 
 
 
 
 
 
 
73 
 
CBTSH BETWEEN 25 – 30 mIU/L(JULY 2001-AUGUST 2017) 
Over the period between July 2001 and August 2017, CBTSH was performed on a 
total of 1,65,637 babies. Of these, 5488 babies had CBTSH between 25-
30mIU/L(3.31%). The ratio of males:females was 1.39:1.Their baseline characteristics 
are shown below in Table 6 
Table 6. Baseline characteristics of babies with CBTSH 25- 30 mIU/L 
(values in parenthesis indicate percentage unless specified otherwise) 
Total screened=1,65,637 
CBTSH >25mIU/L= 5488 
Characteristic  Value 
Birth weight (mean±SD)  2877.49 ± 639.43 
Gestational age 
(mean±SD) 
 38.5 ± 4.59 
Male  3196 (58.2) 
Mode of Delivery    
LSCS 597 (10.9) 
Normal Delivery 3390 (61.7) 
Forceps 534 (10.6) 
Suction cup 525 (10.4) 
Breech 9 (0.2) 
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Of the 5488 babies who were recalled, 4224 babies returned for resampling. (76.96%). 
The mean age at  which the blood tests were repeated was 7.16 ±19.56 days. The 
mean repeat TSH (> 72 hours of age) was 10.13 ± 56.89 mIU/L.  
 
Table 7. Mean cord TSH , repeat TSH and TFT in the >25mIU/L group 
 
 
Table 8. Mean CBTSH in those babies in whom CH was excluded and those with 
diagnosed CH 
 N Mean±SD Range 
Cord TSH in those 
babies in whom CH  
was excluded 
4104 35.32±24.62 25.00 - 247.00 mIU/L 
Cord TSH in those 
babies diagnosed 
with CH 
120 240.04±218.78 25.67 – 1073.00mIU/L 
 
Characteristic Value 
CB TSH (mIU/L) 39.71 ± 50.37 
Age of  resampling (days) 7.16 ±19.56 
Repeat TSH (mIU/L) 10.13 ± 56.89 
Total T4(mcg/dl) 13.73 ± 4.76 
FT4(ng/dl) 1.68 ± 0.76 
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Table 7 shows CBTSH in those babies in whom CH was excluded and those with 
diagnosed CH. Mean CBTSH in those in whom CH was excluded was 35.32±24.62 
mIU/L. However mean CBTSH in those with CH was 240.04±218.78 mIU/L. 
Three babies with CBTSH 149.30,159.00 and 201.00 mIU/L shown as CH excluded 
in the Table above  were severely asphyxiated and  expired/  discharged against  
medical advice  
Table 9. Mean CBTSH trend in >25mIU/L group 
Time Period N  Mean ± SD Range No diagnosed to have 
Congenital 
hypothyroidism(%) 
2001 – 2004 751  35.69 ± 
27.09 
25.00 – 655.00 18(0.04) 
2005 – 2008 1258  41.29 ± 
57.91 
25.03 – 1070.00 25(0.02) 
2009 – 2012 1647  40.91 ± 
58.02 
35.98 ± 15.92 31(0.02) 
2013 – 2017 1832  39.22 ± 
44.33 
25.01 – 750.00 46(0.03) 
The mean cord TSH in the >25mIU/L group was 39.71 ± 50.37. The mean cord TSH 
trend in this group is shown in table.5; the lowest  was 35.69 ± 27.09 mIU/L(2001-
2004) and highest was 41.29 ± 57.91mIU/L(2005-2008). 
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Figure 12. Graph showing the cord TSH trend in the >25mIU/L 
Table 10. Comparison of cord TSH with gestational age, birth weight and mode 
of delivery by means of a Correlation coefficient. 
Characteristic Correlation coefficient (corr) p-value 
Cord TSH and Gestational age 0.004 0.779 
Cord TSH and Birth weight 0.020 0.134 
Cord TSH and Mode of delivery 0.062 <0.001 
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Table 7 shows the comparison of association of cord TSH with gestational age, birth 
weight and mode of delivery by means of a Correlation coefficient. Only the mode of 
delivery(instrumental delivery, forceps and suction cup)  had a significant correlation 
with the cord TSH levels;  instrumental delivery was associated with a higher level of 
CBTSH(p<0.001). 
 
BABIES WITH CBTSH>25 MIU/L  RECALLED,  BUT DID NOT COME 
FOR RESAMPLING 
Table 11. Mean cord TSH among those babies who did not return for repeat 
testing 
Time Period N(%) Mean ± SD Range 
2001 – 2004 109(14.5) 35.21 ± 11.97 25.10 – 98.00 
2005 – 2008 400(27.5) 40.08 ± 58.25 25.10 – 149.30 
2009 – 2012 353(21.4) 35.98 ± 15.92 25.08 – 159.00 
2013 – 2017  395(21.6) 33.70 ± 13.48 25.01 – 201.00 
Of the total of 5488 babies recalled for testing, repeat blood tests were performed in 
4224 babies who returned for sampling.Figure 7 shows the year wise trend of number 
of babies who did not return for repeat testing and their mean cord TSH concentration.  
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Figure 13. Mean Cord TSH trend amongst those babies who did not return for 
repeat testing 
 
Figure 14. Proportion of babies who did not return for confirmatory  sampling . 
In this graph, year of birth is plotted on the “x” axis and proportions are plotted 
on the “y” axis 
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In the period between 2001-2004, only 109 babies missed confirmatory 
sampling.However the years after that saw a significant increase in the babies in 
whom confirmatory sampling could not be performed. 
BABIES CONFIRMED TO HAVE CONGENITAL HYPOTHYROIDISM 
Of the 1,66637 babies screened, diagnosis of congenital hypothyroidism was 
confirmed in 123 babies. 120 of these babies had nuclear imaging done prior to 
treatment initiation.  Of these 53 babies had dyshormonogenesis(enlarged/normal 
gland), 38 had thyroid dysgenesis(agenesis/hypoplasia) and  26 had ectopia.  
 
Figure 15.   Aetiologicalclassification  of confirmed congenital hypothyroidism 
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Figure 16. Graph showing confirmed CH in those recalled for confirmatory  
sampling. In the graph the CBTSH interval is plotted alone the „x‟ axis, the number of 
subjects in each CBTSH interval is plotted along the left “y” axis and the confirmed 
CH along the right “y” axis. 
 
Table 12.Association between CBTSH level and aetiology of CH 
Outcome Frequency -  n Cord TSH 
(mean±SD) 
Range p value 
Dysgenesis 38 300.33 ± 
254.74 
27.5-750 <0.000 
Dyshormonogenes
is 
53 222.39 ± 
214.76 
25.29-731 <0.000 
Ectopic Thyroid 26 198.26 ± 
165.29 
31.59-750 <0.000 
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Table 9 illustrates the mean CBTSH concentration in each aetiology of congenital 
hypothyroidism. Thyroid dysgenesis was associated with the highest CBTSH 300.33 ± 
254.74 mIU/L followed by dyshormonogenesis and ectopia.There was significant 
difference in the mean CBTSH levels of each of these 3 aetiologies. 
Figure 17. Representation of number of babies diagnosed with CH in each interval of 
CBTSH value 
 
Figure 10 represents the number of babies diagnosed with CH in different intervals of 
CBTSH. Eleven of the babies in the 25-40mIU/L group were diagnosed with CH. 
Only 2 of the 15 babies in the 86-100mIU/L grouphad CH, while 80 out of the 93 
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babies in the >100mIU/L had a diagnosis of CH. It is important to note here that 14 % 
of babies who had a CBTSH >100mIU/L did not have CH. 
 
Figure 18. Independence plot with patient ID plotted on the 'x' axis and CBTSH on the 
'y' axis 
In the above scatter plot where CBTSH of all babies with a diagnosis CH are plotted, 
there is a clear pattern in the CBTSH seen above a concentration of 45mIU/L. 
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Figure 19. GG plot demonstrating cord TSH concentrations observed among various 
aetiologies of congenital hypothyroidism 
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FALSE NEGATIVE CASE 
In the last 16 years, only 1 child who was screen 
negative(CBTSH11.8mIU/L)presented with clinical features congenital 
hypothyroidism and confirmed to have athyreosis.  
False negative screen who later was confirmed with CH (n=1)  
GA wks/ B.wt kg  37+2/ 2.5  
CB TSH mIU/L 11.8  
Presentation with CH  Age 16 months:short stature 
myxedema, developmental delay  
TSH mIU/L >750  
T4/FT4 (mcg/dl , ng/dl) <0.3/ <0.1  
Tc 99m scan Thyroid agenesis  
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*Recall rate calculated based on actual  number of babies resampled 
**PPV: positive predictive value 
Table 13.Sensitivity, specificity and  PPV of babies with CBTSH between20- 
30mIU/L 
 
Table 11 shows the sensitivity, specificity, positive predictive value and negative 
predictive value of CBTSH between 20-30mIU/L. CBTSH of 25mIU/L has a 
sensitivity of 99.2% and specificity of  97.5%. As the CBTSH increases to 30mIU/L, 
the sensitivity decreased to 99.1% and specificity improved to 98.5%. Recall rate with 
CBTSH of 25mIU/L was 2.57% and 1.5% with  CBTSH of  30mIU/L.Only those who 
were re-sampled were included to calculate recall rate 
Assumption: one false negative case 
 
Total N 
screened 
 
CBTSH     
(mIU/L) 
 
Recalled 
 
Re-
sampled   
 
Recall 
rate% 
 
True 
positives 
 
**
PPV 
  % 
 
Sensitivity 
% 
 
Specificity 
      % 
N= 
14,742 
20–25  293   195 
 
1.3       0     0          0       98.8 
 
 
 
N= 
1,64,163 
>25 5488   4224 
 
2.57    123 2.9       99.2      97.5 
>26 4928   3824 
 
2.32    119 3.1       99.2     97.8 
>27 4393   3434 
 
2.09    117 3.4       99.1     98 
>28 3911   3070 
 
1.87    117 3.8       99.1     98.2 
>29 3474 2728 
 
1.66    117 4.2       99.1     98.4 
>30 3120 2465 
 
1.5    117 4.7       99.1     98.5 
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a.Under the nonparametric assumption 
b. Null hypothesis: true area = 0.5 
Figure 20. ROC curve for CBTSH data >25mIU/L 
The figure shown above depicts the ROC curve for CBTSH data above 25mIU/L. 
From the graph one can infer that the CBTSH has good sensitivity and is a suitable 
tool for screening for CH. 
Area Under the Curve 
Area Std. Error
a
 Asymptotic 
Sig.
b
 
Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
.931 .017 .000 .898 .963 
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DISCUSSION 
This study is primarily a retrospective analysis of the data from an ongoing newborn 
thyroid screening programme and is by far the largest cohort from a single institution 
in India.  
The ideal sample for newborn thyroid screening is still controversial. While there are 
several advantages as well as disadvantages of using cord blood versus postnatal 
sample for screening, our experience has shown that using cord blood TSH, >99.25% 
of the hospital born babies were screened(Table 1). This includes 8-10% of the babies 
whose cord blood samples were missed and were recaptured prior to discharge from 
the hospital.CMC has to its advantage of being a single private hospital with all 
laboratory facilities in-house and TSH report available within 24 hours.This is a much 
higher coverage than reported by other centres in India using postnatal sampling at 
>24 hours of age ( 86.3% from Chandigarh , 73% from Lucknow)[63,64].This 
becomes particularly relevant as those who did not return for confirmatory sampling 
were ~ 23% in our institution( Table 1) comparable with similar data (15-30% ) from 
other centres. In India, 70- 80 % mothers are discharged within 48 hours after delivery 
and the major reason for missed screening is early post-natal discharge. Post-discharge 
sampling relies on parents to bring back to hospital a “healthy normal” newborn baby 
for “blood” test. Unless we have a health care system with reliable & enthusiastic 
social/ health workers to visit the families at home, postnatal sampling using dried 
blood spot may not serve its purpose of being an effectiveuniversal newborn screening 
tool. 
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Another advantage with CB screening is the possibility for earlier recall, confirmation 
& treatment initiation compared to postnatal sampling .Excluding some babies with 
dyshormonogenesis who needed upto 3 blood tests for confirmation of CH,  treatment 
was initiated at a mean age of 8.4 days after birth in our cohort as compared to 17.7 
days in a screening programme using postnatal sampling[64]. In fact treatment was 
initiated by the end of 2nd week of life in > 90% of our cohort (data not shown). Our 
data was comparable to international data. In New Zealand, using postnatal DBS 
sample for screening, 23% of children were diagnosed within the first week of life and 
by the end of the 2nd and 3rd weeks,  80% and 90% children were diagnosed 
respectively[65] 
The recall rates in screening programmes using CBTSH levels are higher because of 
the wide standard deviation in CBTSH levels. The corrected recall rate in our 
institution based on those who actually returned for confirmatory sampling was 
2.54%. Of these 123 infants were confirmed to have primary CH. This means 
approximately 34 infants were recalled to confirm one infant with CH. In our 
institution,  60-70% of the patients are self-paying and subsidized investigation rates 
are available to the poor,  therefore recall rate was not a major concern for us.Given 
the devastating consequences of missed or delayed initiation of treatment in 
congenital hypothyroidism, this “high” recall rate is still cost-effective. In a small 
cohort from Kerala using a CBTSH cut-off of 16.1mIU/L, the recall rate was 
5.4%[67] 
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Our hospital based incidence is 1: 1346, which is comparable to the rest of India 
(1:1200 in Lucknow, 1: 1700 in Hyderabad , 1:1221 in Delhi) but higher than 
reported by most of the developed countries where it was 1:4000[21] 
OVERALL CBTSH TREND 
The mean CBTSH levels in our data  between January 2004 and January 2017  was  
9.186mIU/L. In a cohort of 450 babies, Prof Meena Desai reported  a lower  CBTSH 
level of 5·069±7·4 μ U/ml in full term babies and 7·88±3·77 μ U/ml in preterm babies 
from Mumbai in 1985[66].A recent data from Kerala also reported lower mean 
CBTSH level {7.82(5.42) μIU/mL}. 
There was significant difference in the mean CBTSH concentration when compared to 
the previous year in the years 2006, 2009, 2011and 2012.The two main factors 
affecting CBTSH level are maternal iodine status and preterm births. Universal 
iodinisation of salt as part of the National iodine deficiency control program was 
launched in India  in 1992.Although the vast majority of our population in Vellore 
uses iodised salt, we do not have any data from our institution  on the iodine status of 
the mothers. 
Another factor that affects the CBTSH level is prematurity. The mean CBTSH levels 
in preterm babies is 2 mIU/L(0.8-5.2) as compared to 9 mIU/L( 1-17.4) in term 
babies[55]. Preterm babies also  have a less marked TSH surge after birth[55].In fact, 
both false positive and false negative screen TSH levels are well documented in high 
risk neonates such as preterm, low birth weight and multiple births[68–70]. 
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Another factor that could be attributed is the increased numbers of instrumental 
deliveries in our population which in itself is an independent risk factor for increased 
in the mean CBTSH as per our study(p=<0.001).This was also reported by another 
recent Indian study where the mode of delivery and perinatal stress factors were 
shown to have  significant impact on CBTSH levels[71].. 
CBTSH BETWEEN 20 – 25mIU/L 
Analysis of babies born with CBTSH 20-24.99  showed an interesting fact. The mean 
age at which confirmatory sampling was done was earlier in the retrospective versus 
the prospective cohort( 6.84±8.53 versus 10 ± 12.06 days). In addition while >96% of 
the recalled babies returned for resampling in 2001-2002, only 40 % returned in 2017. 
There are primarily two factors responsible for this drastic change. The retrospective 
cohort was during the initial few months of introduction of NBS in our 
institutionwhen CBTSH cut-off of 20 mIU/l  was practiced as the standard of care. 
Therefore we were able to explain to the  parents the importance of repeat sampling 
for confirmation of diagnosis. In the current scenario, with CBTSH of 25mIU/l being 
used as the standard  cut-off , we had to recall parents as “part of a study” which was  
entirely voluntary and optional. In addition, in 2001, follow-up of abnormal TSH 
values was intense with even home visits by a social worker. Currently with no field 
staff/ social workers to pursue, the non-responder‟s families are contacted by 
telephone and or letter and the vast majority of families are unwilling to return for 
resampling a “healthy” baby. Focusing on improving awareness regarding the 
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usefulness of NBS for CH through mass media as well as  home visits by health 
workers may improve the coverage.  
This is an important observation in the context of advocating postnatal sampling as a 
screening test for CH in our population. There are many practical difficulties that 
families face in returning to the hospital such as distance from hospital, mode of 
conveyance in order to transport a newborn baby and in our study many patients did 
mention that once the baby is born they spend the next 3 months in their maternal 
home, which is usually in a different city as the hospital and returning for the blood 
test is difficult.  In the developed countries, newborn screening is primarily carried out 
by health workers who collect dried blood spot at home, however this is difficult in 
our  country where the population is large and the health system is overburdened as it 
is.Table 2 shows that majority of the babies who came back for repeat testing in the 
20-25mIU/L group were term babies, of normal birth weight and were born by normal 
vaginal delivery. We may postulate that mothers who were post-operative(LSCS)  
may have had difficulty in travelling back to the hospital for resampling their babies. 
 195 babies with CBTSH 20-24.99 mIU/L were retested, none had congenital 
hypothyroidism. Overall babies with CBTSH 20-24.99mIU/L represented 2.6% of the 
births in 2001-2001 while it decreased to 1.6% of the total births in 2017.Thus 
lowering CBTSH cut-off for recall to any value between 20-< 25mIU/L would mean a 
recall of approximately additional 300 babies/ year which significantly increases the 
the  cost of screening and cause  unnecessary psychological stress in the parents . A 
study from UK reported a 126% increase in recall rate when screen TSH cut-off was 
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lowered to 6.1 from 10mU/L[70].Similar findings have been reported from India also:  
using a CBTSH cut-off of 16.1 , the recall rate was 5.4% in Kerala [72]. 
In the prospective cohort of babies with CBTSH 20-24.99 mIU/L , there was no  
correlation between CBTSH and factors such as birth weight, gestational age and 
mode of delivery. This could be attributed to the small sample size. . 
 
CBTSH BETWEEN 25 – 30mIU/L 
Over the last 17 year period between July 2001 to August 2017 CBTSH was 
performed on 1,65,637 babies of which 5,488 babies had a CBTSH concentration 
above 25mIU/L. The overall mean CBTSH was 39.71 ± 50.37mIU/L, with the 
CBTSH ranging from 25-1070mIU/L. When we divide this data into two groups ie.(i) 
Babies in whom CH was excluded and (ii) Babies in whom CH was diagnosed, as 
expected, the CBTSH in the first group is significantly lower than the second 
group(35.32±24.62 vs 240.04±218.78mIU/L). 
There has been an increase in both the mean CBTSH levels as well as  the number of 
babies diagnosed with CH between 2001-2004 and 2005-2008 (Table 8). This could 
be attributed to the increase in the number of deliveries each year and the 
proportionate increase in the babies who had a CBTSH above 25mIU/L. It is worth 
noting here that the number of deliveries was 7644 in the year 2001 which has now  
nearly doubled to 14,749 deliveries in the year 2016. Therefore with more babies 
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being screened each year, there is an increase in the number of babies diagnosed with 
CH. 
Among the perinatal factors which affect CBTSH level,  mode of delivery is one of 
the important factors.  In our cohort, a significant correlation was seen  between 
CBTSH and mode of delivery(correlation coefficient 0.062, p <0.001) while birth 
weight and gestational age did not show a significant correlation(Table 9). This is 
keeping with the finding of Amir-Mohammad et al in 2013 where they reported a 
significant correlation only between CBTSH and mode of delivery and not with 
gestational age, birth weight or APGAR at 5 mins[73].The increase the CBTSH 
particularly in instrumental deliveries may be explained by the increased perinatal 
stress that the newborn undergoes during a difficult delivery as compared to a normal 
delivery/elective caesarian section[74]. 
Among those who did not return for repeat testing is a small group of babies with 
CBTSH levels as high as 201mIU/L. These babies were severely depressed at birth 
and therefore the high CBTSH can be explained by the perinatal stress[74]. However 
we could not document a normal thyroid function in these babies as they either 
expired or were discharged against medical advice. 
The commonest etiology of primary CH in most in the Caucasian population  is 
thyroid dysgenesis[75]. However in our cohort the proportion of children with  
dyshormonogenesis, dysgenesis and ectopia were 44%, 30% and 21% respectively. 
The  increased proportion of  dyshormongenesis may be explained by prevalence 
ofconsanguinity in our population. Klett et al reported  24-36%  dyshormonogenesis 
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35-42% ectopia  and 22-42% dysgenesis in their cohort [76].Transient CH is known to 
occur with dyshormonogenesis. Interestingly despite having a greater proportion of 
children with dyshormonogenesis, permanence of CH was documented in > 80% of 
our cohort (data not shown).  
The CBTSH level does not usually correlate with the severity of CH, for example, 
athyreosis which represents the most severe form of CH does not always have the 
highest CBTSH level[77]. In our cohort, the highest CBTSH level was observed in  
babies withthyroid dysgenesis followed by those with dyshormonogenesis and 
ectopia,with significant difference in each etiology((p=<0.001, Table 9).However one 
cannot predict the etiology of CH from the CBTSH level as the CBTSH levels varied 
greatly ineach etiology (dysgenesis 25.3-731mIU/L, dyshormonogenesis 27.5-
750mIU/L, ectopia 31.6-750mIU/L). This was further evident from  Figure 9 as  CH 
was ruled out in  13 of the 93 babies with CBTSH >100mIU/L. This  means that 14% 
of the babies in our cohort did not have CH even though they had a CBTSH as high as 
>100mIU/L.   This gives further evidence to the fact  that primary CH cannot be 
diagnosed on the basis of a single abnormal screen TSH value and it should be 
confirmed by repeat thyroid profile showing age appropriate elevated TSH and low 
Free T4 levels. . 
THE IDEAL CBTSH FOR NEW BORN SCREENING 
There is no real consensus on what is the ideal CBTSH for newborn screening of 
CH.This study has tried to address this issue by analysing the effect of lowering and 
increasing the current CBTSH cut-off of 25mIU/L in our screening program.In the 20-
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25mIU/L group, there were no cases of CH and hence the sensitivity is zero(Table 
12). Decreasing the CBTSH to 20mIU/L would mean that an additional 
2%(approximately 300 babies) babies will have to be re-called for confirmatory 
sampling.Considering the fact that a total of 14,742 babies were screened, this number 
becomes relevant. Therefore, we postulate that lowering the CBTSH  cut 
off<25mIU/L may not be cost-effective for our country. 
In the last 16 years we had only one false negative case. This baby who had a CBTSH 
of 11.8 mIU/L returned at 16 months of age with florid congenital hypothyroidism. 
Thus false negativity may occur even in a robust screening programme and newborn 
screening cannot replace careful clinical examination.  If clinical suspicion is high, 
biochemical tests have to be done irrespective of screen results.  
Using a CBTSH cut off of  25mIU/L, the sensitivity was 99.2%, specificity was 
97.5% and PPV was 2.9%. This level of sensitivity and specificity makes CBTSH of 
25mIU/L , as is our current practice, an excellent choice as a screening test. If we 
increase the cut off from 25mIU/L to 30mIU/L, the   specificity would increase and 
recall rate decrease by 1%, however 6 babies with CH who had CBTSH levels 25-30 
mIU/L would have been missed(Figure 9). By the time these „missed” cases are 
diagnosed clinically, irreversible developmental delay may have occurred. The impact 
of a child with significant developmental delay on the family is enormous and cannot 
be quantified 
One of the biggest problems with analyzing the sensitivity and specificity of the range 
of CBTSH levels (20-30 mIU/L) was verification bias well documented with such 
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screening tests[78]. The gold standard for diagnosing congenital hypothyoidism is by 
demonstrating elevated TSH level and low Free T4 level in the confirmatory 
sampling. However in our screening programme, only those with CBTSH > 25 mIU/L 
as per the existing practice and CBTSH > 20 during the study period had a 
confirmatory sample done and CH ruled out or confirmed. As only one child who was 
screen negative from our cohort presented with CH later on, in our analysis, we have 
included one as false negative on the assumption that all those who were screen 
negative and did not undergo the gold standard test were disease free. Therefore there 
is a verification bias in the analysis and this may have affected the actual sensitivity 
and specificity reported in this study. 
Although we are  aware of this limitation, it was not feasible for all children (screen 
negative and positive) to undergo the “gold standard” repeat  sampling because of the 
practical difficulties and the huge expenditure involved. We have probably minimized 
the verification bias by resampling 195 children with CBTSH  below our standard cut-
off.  The large sample size, longitudinal nature of our screening programme and a long 
follow-up of 16 years also may have minimized the verification bias. 
There is no consensus on what is the ideal CBTSH for newborn screening for CH. The 
decision to increase or decrease the cut off should be made after consideration of 
many factors such as sensitivity, specificity, acceptable re-call rate for that population 
etc. While increasing the screen cut-off value reduces the recall rate it reduces the 
sensitivity of the test, in other words, may miss few children with CH. At the same 
time, should  resource limited countries have a higher screen cut-off and hope to 
diagnose and treat the vast majority of children with CH while being aware that few 
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children with “mild CH” may have been missed?. With our experience over the last 16 
years  with a successful CBTSH based screening program we propose CBTSH of 
25mIU/L as the ideal screen cut-off  for our population. 
India, being one of the fastest growing countries in terms of population and economy, 
a healthy population is most vital if it really needs to capitalize on this population 
dividend. As per the CES data of 2009, the overall number of institutional deliveries 
(rural + urban) have increased from 38.7%to 72.9%[56]. With this increase in the 
percentage of institutional deliveries, implementation of newborn screening would be 
another step in the right direction to ensure a healthy population.  
Mental retardation(MR) as a condition not only affects the person having the disease 
but also causes significant psychological and financial stress to their family and care 
givers[79,80]. Congenital hypothyroidism, being one of the most preventable and 
easily treatable causes of MR, makes it a suitable candidate  for  universal new born 
screening. 
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CONCLUSIONS 
1.  More than 99% of the babies born in our institution were screened for congenital 
hypothyroidism using cord blood samples. With significant increase in the number of 
institutional deliveries in India, CBTSH is the most practical and cost effective 
screening tool for CH in our country.. 
2. Loweringthe CBTSH to 20mIU/L would mean that an additional 2%(approximately 
300 babies) babies will have to be re-called for confirmatory sampling. 
3. Therefore lowering the CBTSH  cut off below 25mIU/L may not be cost-effective 
for our country. 
4. Increasing the CBTSH cut-off to 30 mIU/L may lower the recall rate by 1%, 
however 6 babies with CH would have been missed. The devastating consequences of 
a late diagnosis of CH in these babies would have been enormous.  
5. A CBTSH of 25mIU/L, with its high sensitivity and specificity, makes it an 
excellent choice as a newborn screening tool. 
6. With the availability of simple, easy and  low cost diagnostic and treatment options 
for congenital hypothyroidism, with an excellent outcome, universal newborn 
screening program should be initiated at the earliest in India. . 
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LIMITATIONS 
1. In the initial years of our NBS, TSH levels were not performed in dilution, so we do 
not have absolute baseline values for few subjects.  
2. Only 195 babies with CBTSH <25mIU/L had undergone confirmatory testing with 
the gold standard test. Therefore there is a verification bias in the analysis and this 
may have affected the actual sensitivity and specificity reported in this study. 
Resampling few screen negative babies, large sample size, longitudinal nature of our 
screening programme and a long follow-up of 16 years may have minimized the 
verification bias. 
3. Missing data of some of the babies (gestational age, birth weight, mode of delivery) 
was obtained from registers and patient information available from computer scanned 
charts. In our institution, computerization of patient‟s records was done from 2010 
onwards. Therefore some of the missing data prior to 2010could not be verified. 
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Proforma for newborns with cord TSH between 20mIU/L to 24.9mIU/L 
 
1. Serial no :  
 
2. Name      :  
 
3. Hospital number : 
 
4. Sex :                                                    1. Male               2. Female 
 
5. Village / Town / City name : 
 
6. Was maternal thyroid function test done during prenanacy: 1.  Yes        2. No  
 
7. Was mother on Thyroxine supplementation during pregnancy: 1.  Yes    2. No 
 
8. Use of iodised salt at home :                              1. Yes                 2. No 
 
9. Family history of Thyroid disease:                                                            1.Yes                  
2. No 
 
10. If yes, Specify   _____________________________ 
 
 
 
 
 
 
 
117 
 
Patient information sheet 
 
Ideal cord blood TSH cut-off level for mass newborn thyroid screening  in the 
South Indian population 
 
Why do we need this test? 
      Thyroid gland is a gland in the neck which produces thyroid hormones which are 
very important for the physical and mental development of children. Some children 
are born without a properly functioning thyroid gland and this condition is called 
congenital hypothyroidism (CH). If thyroid hormone supplements are started for these 
children within 2-3 weeks of birth their development is excellent. However it is 
difficult to diagnose congenital hypothyroidism at birth just by seeing the baby as the 
clinical features are very minimal at birth. Therefore it is important to screen all 
children at birth for CH before the clinical features appear. Very few hospitals in India 
screen newborn babies at birth for CH.  All babies born in Christian Medical College 
Vellore  are screened for CH  since June 2001.  The newborn screening is done by 
collecting few drops of blood from the baby‟s umbilical cord  at birth (cord blood) and 
analyzing TSH level . Currently all babies with cord blood TSH > 25 Miu/l are called 
again for repeat tests and confirmation of diagnosis.  
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We are planning on a study to assess whether this cut-off level of 25 Miu/L is optimal. 
Therefore over the next one year we intend to recall all babies with cod blood TSH 
20-25 Miu/L for repeat testing.  
Do you think my baby may be affected? 
When we ask you return on day three for repeat blood tests it does not mean that your 
baby definitely has the disease. It only means that screening test performed on the 
cord blood was higher than the accepted cut off and that your baby may have a chance 
of having congenital hypothyroidism. The diagnosis of congenital hypothyroidism can 
be made only after seeing  the repeat blood tests.  
What do we do for the test? 
If your baby‟s cord blood TSH is between 20-25 you will be contacted for 
participation n this study. If you agree to paraticipate we will repeat a blood sample 
after 3 days of age. The blood sample will be collected by a paediatrician or an 
experienced nurse in our Project room located on the 5
th
 floor of the ISSCC building. 
You may directly  bring the baby to this location without any prior appointment.  
Will we tell you the result of the test? 
Yes. The results of the test will be told to you by telephone by the study team.  
What happens if my baby has a positive test? 
If the repeat testing is abnormal, your baby will be seen by a paediatric 
endocrinologist as soon as possible and treatment will be initiated.  
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Do I have to pay for the test? 
No, as this test is being done as a part of a research project and it is  done free of cost. 
Could I opt out of the study at any point? 
Yes, you could opt out at any point during the course of the study. 
 
If you have any questions, then please contact me on: 
Dr Praveen George Paul 
PG Registrar 
Department of Paediatrics unit I 
 
CMC Vellore 
Mob no : 9994882234 
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Informed Consent Form for Subjects 
 
Ideal cord blood TSH cut-off level for mass newborn thyroid 
screening  in the South Indian population 
 
Number: ____________ 
 
Subject’s Name: _________________________________________ 
 
Date of Birth / Age: ___________________________ 
 
(Subject) 
 
(i)  I confirm that I have read and understood the information sheet dated ____________ for 
the above study and have had the opportunity to ask questions. [  ] 
(ii)  I understand that my participation in the study is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights being affected. [  ] 
(iii)  I understand that the Sponsor of the clinical trial, others working on the Sponsor’s behalf 
(delete as appropriate), the Ethics Committee and the regulatory authorities will not need my 
permission to look at my health records both in respect of the current study and any further 
research that may be conducted in  
relation to it, even if I withdraw from the trial. I agree to this access. However, I understand that my 
identity will not be revealed in any information released to third parties or published. [  ] 
(iv)  I agree not to restrict the use of any data or results that arise from this study provided such 
a use is only for scientific purpose(s). [  ] 
(v)  I agree to take part in the above study. [  ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
 
Date: _____/_____/______ 
 
 
121 
 
 
 
 
Signatory’s Name: _________________________________         Signature:  
 
Or 
 
 
 
 
 
 
Representative: _________________ 
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________ 
 
 
Signature of the Investigator: ________________________ 
 
Date: _____/_____/______ 
 
Study Investigator’s Name: _________________________ 
 
 
Signature or thumb impression of the Witness: ___________________________ 
 
Date: _____/_____/_______ 
 
Name & Address of the Witness: __________________ 






















